General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Primary Care

Building upon our strong heritage in meeting the unmet needs of Primary Care patients, Novartis is focused on improving the lives of the hundreds of millions of people with respiratory diseases. We remain committed to providing the right drug to the right patient at the right time to treat chronic obstructive pulmonary disease and asthma--both major public health issues.

The portfolio includes:

  • Arcapta Neohaler/Onbrez Breezhaler (indacaterol)